openPR Logo
Press release

Genital Herpes Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Moderna Therapeutics, Vaxxit, Nanoviricides, BioNTech, GlaxoSmithKline, United BioPharma

05-15-2024 08:40 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Genital Herpes Pipeline and Clinical Trials Assessment 2024:

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Genital Herpes pipeline constitutes key companies continuously working towards developing Genital Herpes treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Genital Herpes Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Genital Herpes Market.

The Genital Herpes Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Genital Herpes Pipeline Report: https://www.delveinsight.com/sample-request/genital-herpes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Genital Herpes treatment therapies with a considerable amount of success over the years.
• Genital Herpes companies working in the treatment market are Moderna Therapeutics, Vaxxit, Nanoviricides, BioNTech, GlaxoSmithKline, United BioPharma, Heidelberg ImmunoTherapeutics, AiCuris, and others, are developing therapies for the Genital Herpes treatment
• Emerging Genital Herpes therapies in the different phases of clinical trials are- Attenuated vaccine against HSV 1&2, HSV "Genital lesions" Skin cream/Lotion, BNT 163, GSK 3943104A, UB 621, HDIT101, Pritelivir, and others are expected to have a significant impact on the Genital Herpes market in the coming years.
• In March 2024, Assembly Bio, a biopharmaceutical company headquartered in the United States, intends to commence four clinical trials for its infectious disease pipeline candidates in the current year. CEO Jason Okazaki stated that the company aims to start two trials in the first half of the year and two in the second half, with a focus on herpes simplex virus 2 (HSV2), hepatitis B, and hepatitis D (HDV).
• In August 2022, an observational clinical research to identify the baseline traits of patients with recurrent symptomatic herpes simplex virus type 2 infection (HSV-2) has begun, according to Rational Vaccines Inc.

Genital Herpes Overview
Genital herpes is a common sexually transmitted infection (STI) caused by the herpes simplex virus (HSV). There are two types of HSV that can cause genital herpes: HSV-1 and HSV-2. HSV-2 is the more common cause of genital herpes, but HSV-1, typically associated with oral herpes, can also cause genital infections through oral-genital contact.

Get a Free Sample PDF Report to know more about Genital Herpes Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/genital-herpes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Genital Herpes Drugs Under Different Phases of Clinical Development Include:
• mRNA 1608: Moderna Therapeutics
• Attenuated vaccine against HSV 1&2: Vaxxit
• HSV "Genital lesions" Skin cream/Lotion: Nanoviricides
• BNT 163: BioNTech
• GSK 3943104A: GlaxoSmithKline
• UB 621: United BioPharma
• HDIT101: Heidelberg ImmunoTherapeutics
• Pritelivir: AiCuris

Genital Herpes Route of Administration
Genital Herpes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Genital Herpes Molecule Type
Genital Herpes Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Genital Herpes Pipeline Therapeutics Assessment
• Genital Herpes Assessment by Product Type
• Genital Herpes By Stage and Product Type
• Genital Herpes Assessment by Route of Administration
• Genital Herpes By Stage and Route of Administration
• Genital Herpes Assessment by Molecule Type
• Genital Herpes by Stage and Molecule Type
DelveInsight's Genital Herpes Report covers around products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Genital Herpes product details are provided in the report. Download the Genital Herpes pipeline report to learn more about the emerging Genital Herpes therapies at:
https://www.delveinsight.com/sample-request/genital-herpes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Genital Herpes Therapeutics Market include:
Key companies developing therapies for Genital Herpes are - AiCuris, United BioPharma, Heidelberg ImmunoTherapeutics, Genocea Biosciences, Agenus, Fresh Tracks Therapeutics, Sanofi, GlaxoSmithKline, and others.

Genital Herpes Pipeline Analysis:
The Genital Herpes pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Genital Herpes with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Genital Herpes Treatment.
• Genital Herpes key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Genital Herpes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Genital Herpes market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Genital Herpes drugs and therapies-
https://www.delveinsight.com/sample-request/genital-herpes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Genital Herpes Pipeline Market Drivers
• Increasing awareness among the population regarding genital herpes infection, availability of high sensitivity and specificity of nucleic acid amplification based kits test type are some of the important factors that are fueling the Genital Herpes Market.

Genital Herpes Pipeline Market Barriers
• However, accessibility of diagnostic services, Insufficient R&D initiatives, pricing pressures, and stringent regulations, lack of novel strategies to prevent or suppress HSV-2 infection and other factors are creating obstacles in the Genital Herpes Market growth.

Scope of Genital Herpes Pipeline Drug Insight
• Coverage: Global
• Key Genital Herpes Companies: Moderna Therapeutics, Vaxxit, Nanoviricides, BioNTech, GlaxoSmithKline, United BioPharma, Heidelberg ImmunoTherapeutics, AiCuris, and others
• Key Genital Herpes Therapies: Attenuated vaccine against HSV 1&2, HSV "Genital lesions" Skin cream/Lotion, BNT 163, GSK 3943104A, UB 621, HDIT101, Pritelivir, and others
• Genital Herpes Therapeutic Assessment: Genital Herpes current marketed and Genital Herpes emerging therapies
• Genital Herpes Market Dynamics: Genital Herpes market drivers and Genital Herpes market barriers

Request for Sample PDF Report for Genital Herpes Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/genital-herpes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Genital Herpes Report Introduction
2. Genital Herpes Executive Summary
3. Genital Herpes Overview
4. Genital Herpes- Analytical Perspective In-depth Commercial Assessment
5. Genital Herpes Pipeline Therapeutics
6. Genital Herpes Late Stage Products (Phase II/III)
7. Genital Herpes Mid Stage Products (Phase II)
8. Genital Herpes Early Stage Products (Phase I)
9. Genital Herpes Preclinical Stage Products
10. Genital Herpes Therapeutics Assessment
11. Genital Herpes Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Genital Herpes Key Companies
14. Genital Herpes Key Products
15. Genital Herpes Unmet Needs
16 . Genital Herpes Market Drivers and Barriers
17. Genital Herpes Future Perspectives and Conclusion
18. Genital Herpes Analyst Views
19. Appendix
20. About DelveInsight

Latest Reports:

Aneurysmal Subarachnoid Hemorrhage Market https://www.delveinsight.com/report-store/aneurysmal-subarachnoid-hemorrhage-sah-market
DelveInsight's "Aneurysmal Subarachnoid Hemorrhage (SAH) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Aneurysmal Subarachnoid Hemorrhage (SAH), historical and forecasted epidemiology as well as the Aneurysmal Subarachnoid Hemorrhage (SAH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Angelman Syndrome Market https://www.delveinsight.com/report-store/angelman-syndrome-market-forecast
DelveInsight's "Angelman Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Angelman Syndrome, historical and forecasted epidemiology as well as the Angelman Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Autoimmune Pulmonary Alveolar Proteinosis Market https://www.delveinsight.com/report-store/autoimmune-pulmonary-alveolar-proteinosis-apap-market
DelveInsight's "Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Market Insights, Epidemiology and Market Forecast - 2032" report delivers an in-depth understanding of Autoimmune pulmonary alveolar proteinosis, historical and forecasted epidemiology as well as Autoimmune pulmonary alveolar proteinosis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Cardiovascular Calcification Market https://www.delveinsight.com/report-store/cardiovascular-calcification-market
DelveInsight's "Cardiovascular Calcification Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Cardiovascular Calcification, historical and forecasted epidemiology as well as the Cardiovascular Calcification market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Charcot Marie Tooth Disease Market https://www.delveinsight.com/report-store/charcot-marie-tooth-disease-market
DelveInsight's 'Charcot-Marie-Tooth Disease Market Insights, Epidemiology, and Market Forecast 2032' report deliver an in-depth understanding of the Charcot-Marie-Tooth Disease, historical and forecasted epidemiology as well as the Charcot-Marie-Tooth Disease market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Genital Herpes Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Moderna Therapeutics, Vaxxit, Nanoviricides, BioNTech, GlaxoSmithKline, United BioPharma here

News-ID: 3498135 • Views:

More Releases from DelveInsight Business Research

Treg Cell-Based Therapies Pipeline Analysis, 2024 Updates | Latest FDA, EMA, and PMDA Approvals | Rapa Therapeutics, Orca Bio, Caladrius Biosciences, Sangamo Therapeutics, Quell Therapeutics, Coya Therapeutics, Sonoma Biotherapeutics, GentiBio, AstraZenec
Treg Cell-Based Therapies Pipeline Analysis, 2024 Updates | Latest FDA, EMA, and …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Treg Cell-Based Therapies pipeline constitutes key companies continuously working towards developing Treg Cell-Based Therapies treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Treg Cell-Based Therapies Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also
Non-Cystic Fibrosis Bronchiectasis Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Insmed Inc, AstraZeneca, Zambon, CSL Behring, Chiesi Farmaceutici
Non-Cystic Fibrosis Bronchiectasis Pipeline Drugs Analysis Report, 2024 Updates: …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Non-Cystic Fibrosis Bronchiectasis pipeline constitutes 16+ key companies continuously working towards developing 17+ Non-Cystic Fibrosis Bronchiectasis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Non-Cystic Fibrosis Bronchiectasis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The
Chronic Rhinosinusitis with Nasal Polyps Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | AstraZeneca, Amgen, Pfizer, Trellis Bioscience, GSK, Insmed, Lyra Therapeutics
Chronic Rhinosinusitis with Nasal Polyps Pipeline Analysis 2024: FDA Approvals, …
(Albany, USA) As per DelveInsight's assessment, globally, about 10+ key pharma and biotech companies are working on 10+ pipeline drugs in the Chronic Rhinosinusitis with Nasal Polyps therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years. "Chronic Rhinosinusitis with Nasal Polyps Pipeline Insight
Advanced Ovarian Cancer Market Forecast 2032: FDA, EMA, PDMA Approvals, Clinical Trials, Epidemiology, Therapies, Companies by DelveInsight | Oregovomab, Stenoparib, DP-303c, more.
Advanced Ovarian Cancer Market Forecast 2032: FDA, EMA, PDMA Approvals, Clinical …
As per DelveInsight's assessment, globally, about 50+ key pharma and biotech companies are working on 50+ pipeline drugs in the Advanced Ovarian Cancer therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years. "Advanced Ovarian Cancer Pipeline Insight, 2024" report by DelveInsight provides a

All 5 Releases


More Releases for Genital

Genital Warts Market to Witness Growth by 2032, Estimates DelveInsight
DelveInsight's "Genital Warts Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Genital Warts, historical and forecasted epidemiology as well as the Genital Warts market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Genital Warts market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Genital Warts market size
Genital Herpes - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Genital Herpes - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Genital Herpes - Pipeline Review, H2 2017, provides an overview of the Genital Herpes (Infectious Disease) pipeline landscape. Genital herpes is a common sexually transmitted infection that affects both men and women. Genital herpes is caused
Global Clinical Trials Review for Genital Herpes, H2, 2017
"The Report Genital Herpes Global Clinical Trials Review, H2, 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" ​Genital Herpes Global Clinical Trials Review, H2, 2017 Summary GlobalDatas clinical trial report, Genital Herpes Global Clinical Trials Review, H2, 2017" provides an overview of Genital Herpes clinical trials scenario. Get Sample copy of this Report @​ https://www.marketresearchreports.biz/sample/sample/1335055 This report provides top line data relating to the
Genital Herpes Market- Opportunity Analysis and Forecasts to 2023
"The Report OpportunityAnalyzer: Genital Herpes - Opportunity Analysis and Forecasts to 2023 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" About Genital Herpes Market Genital herpes (GH) is a life-long viral infection of the genitalia and urogenital tract. It is one of the most common sexually transmitted infections (STIs) and is a leading cause of genital ulcers around the world. Patients with GH
Genital Herpes - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Genital Herpes - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Genital Herpes - Pipeline Review, H1 2017, provides an overview of the Genital Herpes (Infectious Disease) pipeline landscape. Genital herpes is a common sexually transmitted infection that affects both men and women. Genital herpes is caused
Genital Herpes - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Thyroid Cancer - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thyroid Cancer – Pipeline Review, H1 2017, provides an overview of the Thyroid Cancer (Oncology) pipeline landscape. Thyroid cancer is a cancer that starts in the thyroid gland. Symptoms include lump that can be felt through